Taselisib - Genentech/Chugai Pharmaceutical

Drug Profile

Taselisib - Genentech/Chugai Pharmaceutical

Alternative Names: GDC 0032; RG-7604

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; Netherlands Cancer Institute
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Benzazepines; Oxazepines; Pyrazoles; Small molecules; Triazoles
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer
  • Phase II/III Non-small cell lung cancer
  • Phase I/II Growth disorders; Gynaecological cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase III SANDPIPER trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 04 May 2018 Phase I development in Solid tumours is ongoing (Chugai pipeline, May 2018)
  • 03 May 2018 Genentech and Vanderbilt-Ingram Cancer Center suspends patient enrolment due to interim analysis in a phase Ib/II trial in Breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (PO) (NCT02457910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top